Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)

Core Viewpoint - Dianthus Therapeutics Inc. (NASDAQ:DNTH) is identified as one of the most shorted biotech stocks with significant upside potential, as highlighted by recent price target increases from Guggenheim and Oppenheimer [1][3]. Group 1: Price Target Adjustments - Guggenheim raised its price target for Dianthus Therapeutics from $100 to $200, indicating an upside potential of nearly 207% [1]. - Oppenheimer increased its price target from $62 to $125 while maintaining an Outperform rating, noting a year-to-date share gain of 22% compared to a 5% rise in the XBI index [3]. Group 2: Sales Projections - Guggenheim projects global peak sales of approximately $2.8 billion from CIDP patients and around $2 billion from the gMG indication, following updates to its sales model [2]. Group 3: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing treatments for severe autoimmune and inflammatory diseases through highly selective monoclonal antibodies, particularly their lead candidate claseprubart [4].